Trials / Unknown
UnknownNCT03560882
A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies
A Pilot Trial of Atorvastatin in p53-Mutant and p53 Wild-Type Malignancies
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Joaquina Baranda · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a window-of-opportunity trial to determine if atorvastatin given for 1 to 4 weeks at a dose of 80 milligrams per day (mg/day) is sufficient to decrease the level of conformational mutant tumor protein 53 (p53) in malignant diseases (solid tumor and relapsed Acute Myeloid Leukemia (AML)).
Conditions
- Malignant Disease
- Solid Tumor
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- Cancer
- Relapsed Hematologic Malignancy
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atorvastatin | Atorvastatin tablet, 80mg |
Timeline
- Start date
- 2018-07-19
- Primary completion
- 2022-10-14
- Completion
- 2025-08-01
- First posted
- 2018-06-18
- Last updated
- 2024-03-21
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03560882. Inclusion in this directory is not an endorsement.